Search

Your search keyword '"Janneke van der Woude C"' showing total 5 results
Start Over Author "Janneke van der Woude C" Publication Year Range This year
5 results on '"Janneke van der Woude C"'

1. Interobserver agreement of current and new proposed endoscopic scores for postoperative recurrence in Crohn’s disease

Author

Bak, Michiel T.J., Hammoudi, Nassim, Allez, Matthieu, Silverberg, Mark S., Schellekens, Isa M., Erler, Nicole S., Dijkstra, Gerard, Romberg-Camps, Mariëlle, de Boer, Nanne K.H., Jansen, Sita V., van der Marel, Sander, Horjus, Carmen S., Visschedijk, Marijn C., Goetgebuer, Rogier L., van Dop, Willemijn A., Hoekstra, Jildou, Bodelier, Alexander G.L., Molendijk, Ilse, Derikx, Lauranne A.A.P., van Schaik, Fiona D.M., West, Rachel L., Duijvestein, Marjolijn, Janneke van der Woude, C., van Ruler, Oddeke, and de Vries, Annemarie C.

Published
2024
Full Text
View/download PDF

2. Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy

Author

Korgaard, Julie, Vestergaard, Thea, Lystbæk, Uffe Lund, Berg, Anne, Mikkelsen, Anette Tyrsted, Holm, Anne Marie, Hansen, Annebirthe Bo, Mathiesen, Ole, Jensen, Jette Krüger, Neumann, Lone, Boris, Jane, Lemming, Marianne, Rahbek, Marianne, Søresen, Heidi Gram, Storkholm, Marie Højriis, Ziska, Jeanette, Vestergaard, Else Marie, Bøggild Ipsen, Sidsel Elisabeth, Gram, Jørgen, Brixen, Gunhild, Westergaard, Hanne Brix, Friis-Hansen, Lennart Jan, Olsen, Bettina Friis, Fischer, Heidi, Bjerrum, Poul Jannik, Ibsen, Anne Haahr, Jaeger, Vibeke, Madsen, Jesper Clausager, Møller, Lars Alling, Søeby, Karen, Damm, Jane Hansen, Hilsted, Linda, Christiansen, Lone, Sharif, Heidi, Johansen, Britt Strøm, Dahl, Karina Mattebjerg, Langholz, Ebbe, Kamstrup, Pia R., Jochumsen, Anja, Huusom, Lene Drasbek, Bathum, Lise, Wilken-Jensen, Charlotte, Julsgaard, Mette, Wieringa, Jantien W., Baunwall, Simon M.D., Bibby, Bo M., Driessen, Gertjan J.A., Kievit, Linda, Brodersen, Jacob B., Poulsen, Anja, Kjeldsen, Jens, Hansen, Mette M., Tang, Hai Q., Balmer, Christina L., Glerup, Henning, Seidelin, Jakob B., Haderslev, Kent V., Svenningsen, Lise, Wildt, Signe, Juel, Mie A., Neumann, Anders, Fuglsang, Jens, Jess, Tine, Haase, Anne-Mette, Hvas, Christian L., Kelsen, Jens, and Janneke van der Woude, C.

Published
2024
Full Text
View/download PDF

3. Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease:Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies

Author

Ten Bokkel Huinink, Sebastiaan, Thomassen, Doranne, Steyerberg, Ewout W., Pauwels, Renske W.M., Casanova, Maria J., Bouguen, Guillaume, Mak, Joyce W.Y., Molnár, Tamas, Lobo, Alan J., Seidelin, Jacob B., Amiot, Aurelien, D'Haens, Geert, Rivière, Pauline, Guidi, Luisa, Bor, Renata, Lin, Wei Chen, Peyrin-Biroulet, Laurent, Gisbert, Javier P., Janneke van der Woude, C., de Vries, Annemarie C., Ten Bokkel Huinink, Sebastiaan, Thomassen, Doranne, Steyerberg, Ewout W., Pauwels, Renske W.M., Casanova, Maria J., Bouguen, Guillaume, Mak, Joyce W.Y., Molnár, Tamas, Lobo, Alan J., Seidelin, Jacob B., Amiot, Aurelien, D'Haens, Geert, Rivière, Pauline, Guidi, Luisa, Bor, Renata, Lin, Wei Chen, Peyrin-Biroulet, Laurent, Gisbert, Javier P., Janneke van der Woude, C., and de Vries, Annemarie C.

Abstract

BACKGROUND: The risk of relapse after anti-tumour necrosis factor [TNF] therapy discontinuation in Crohn's disease patients with perianal fistulas [pCD] is unclear. We aimed to assess this risk. METHODS: A systematic literature search was conducted to identify cohort studies on the incidence of relapse following anti-TNF discontinuation in pCD patients. Individual participant data were requested from the original study cohorts. Inclusion criteria were age ≥16 years, pCD as a (co)indication for start of anti-TNF therapy, more than three doses, and remission of luminal and pCD at anti-TNF discontinuation. The primary outcome was the cumulative incidence of CD relapse using Kaplan-Meier estimates. Secondary outcomes included response to re-treatment and risk factors associated with relapse as assessed by Cox regression analysis. RESULTS: In total, 309 patients from 12 studies in ten countries were included. The median duration of anti-TNF treatment was 14 months [interquartile range 5.8-32.5]. Most patients were treated for pCD without active luminal disease [89%], received first-line anti-TNF therapy [87%], and continued immunomodulatory therapy following anti-TNF discontinuation [78%]. The overall cumulative incidence of relapse was 36% (95% confidence interval [CI] 25-48%) and 42% [95% CI 32-53%] at 1 and 2 years after anti-TNF discontinuation, respectively. Risk factors for relapse included smoking (hazard ratio [HR] 1.5 [1.0, 2.1]) and history of proctitis (HR 1.7 [1.1, 2.5]). The overall re-treatment response rate was 82%. CONCLUSIONS: This individual participant data meta-analysis, on predominantly patients with pCD without active luminal disease and first-line anti-TNF therapy, shows that over half of patients remain in remission 2 years after anti-TNF discontinuation. Therefore, anti-TNF discontinuation may be considered in this subgroup.

Published
2024

4. Infant ustekinumab Clearance, Risk of Infection, and Development after exposure during pregnancy

Author

Julsgaard, Mette, primary, Wieringa, Jantien W., additional, Baunwall, Simon M.D., additional, Bibby, Bo M., additional, Driessen, Gertjan J.A., additional, Kievit, Linda, additional, Brodersen, Jacob B., additional, Poulsen, Anja, additional, Kjeldsen, Jens, additional, Hansen, Mette M., additional, Tang, Hai Q., additional, Balmer, Christina L., additional, Glerup, Henning, additional, Seidelin, Jakob B., additional, Haderslev, Kent V., additional, Svenningsen, Lise, additional, Wildt, Signe, additional, Juel, Mie A., additional, Neumann, Anders, additional, Fuglsang, Jens, additional, Jess, Tine, additional, Hasse, Anne-Mette, additional, Hvas, Christian L., additional, Kelsen, Jens, additional, and Janneke van der Woude, C., additional

Published
2024
Full Text
View/download PDF

5. Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies.

Author

Ten Bokkel Huinink S, Thomassen D, Steyerberg EW, Pauwels RWM, Casanova MJ, Bouguen G, Mak JWY, Molnár T, Lobo AJ, Seidelin JB, Amiot A, D'Haens G, Rivière P, Guidi L, Bor R, Lin WC, Peyrin-Biroulet L, Gisbert JP, Janneke van der Woude C, and de Vries AC

Subjects
Humans, Adolescent, Infliximab therapeutic use, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor Inhibitors therapeutic use, Recurrence, Necrosis complications, Treatment Outcome, Retrospective Studies, Crohn Disease complications, Crohn Disease drug therapy, Rectal Fistula etiology, Rectal Fistula complications
Abstract

Background: The risk of relapse after anti-tumour necrosis factor [TNF] therapy discontinuation in Crohn's disease patients with perianal fistulas [pCD] is unclear. We aimed to assess this risk., Methods: A systematic literature search was conducted to identify cohort studies on the incidence of relapse following anti-TNF discontinuation in pCD patients. Individual participant data were requested from the original study cohorts. Inclusion criteria were age ≥16 years, pCD as a (co)indication for start of anti-TNF therapy, more than three doses, and remission of luminal and pCD at anti-TNF discontinuation. The primary outcome was the cumulative incidence of CD relapse using Kaplan-Meier estimates. Secondary outcomes included response to re-treatment and risk factors associated with relapse as assessed by Cox regression analysis., Results: In total, 309 patients from 12 studies in ten countries were included. The median duration of anti-TNF treatment was 14 months [interquartile range 5.8-32.5]. Most patients were treated for pCD without active luminal disease [89%], received first-line anti-TNF therapy [87%], and continued immunomodulatory therapy following anti-TNF discontinuation [78%]. The overall cumulative incidence of relapse was 36% (95% confidence interval [CI] 25-48%) and 42% [95% CI 32-53%] at 1 and 2 years after anti-TNF discontinuation, respectively. Risk factors for relapse included smoking (hazard ratio [HR] 1.5 [1.0, 2.1]) and history of proctitis (HR 1.7 [1.1, 2.5]). The overall re-treatment response rate was 82%., Conclusions: This individual participant data meta-analysis, on predominantly patients with pCD without active luminal disease and first-line anti-TNF therapy, shows that over half of patients remain in remission 2 years after anti-TNF discontinuation. Therefore, anti-TNF discontinuation may be considered in this subgroup., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results